ACTION: Notice of application.

SUMMARY: S&B Pharma LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2022. Such persons may also file a written request for a hearing on the application on or before April 26, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on December 24, 2021, S&B Pharma LLC, 405 South Motor Avenue, Azusa, California 91702, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I
Marihuana	7360	I
Tetrahydrocannabinols	7370	I
Amphetamine	1100	II
Methamphetamine	1105	II
Lisdexamfetamine	1205	II
Methylphenidate	1724	II
Pentobarbital	2270	II
4-Anilino-N-Phenethyl-4-Piperidine (ANPP).	8333	II
Tapentadol	9780	II
Fentanyl	9801	II

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates for formulation and analytical development purposes or for sale to its customers. In reference to dug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

Matthew J. Strait,

Deputy Assistant Administrator.

[FR Doc. 2022–04062 Filed 2–24–22; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–974]

Bulk Manufacturer of Controlled Substances Application: Cedarburg Pharmaceuticals

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Cedarburg Pharmaceuticals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2022. Such persons may also file a written request for a hearing on the application on or before April 26, 2022.

ADDRESSES: DEA requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *http://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *http://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.''

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on August 27, 2021, Cedarburg Pharmaceuticals, 870 Badger Circle, Grafton, Wisconsin 53024–0000, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Lysergic Acid Diethylamide.	7315	I
Tetrahydrocannabinols	7370	I
4-Bromo-2,5-Dimethoxyphenethylamine.	7392	I
3,4-Methylenediocyamphetamine.	7400	I
3.4-Methylenedioxymethamphetamine.	7405	I
5-Methoxy-N-N-dimethltryptamine.	7431	I
Dimethyltryptamine	7435	I
Psilocybin	7437	I
Psilocyn	7438	I
Methylphenidate	1724	II
Nabilone	7379	II
4-Anilino-N-Phenethyl-4-Piperidine (ANPP).	8333	II
Fentanyl	9801	II

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. In reference to the drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture as synthetic. No other activity for this drug code is authorized for this registration.

Matthew J. Strait,

Deputy Assistant Administrator.

[FR Doc. 2022–04064 Filed 2–24–22; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–964]

Bulk Manufacturer of Controlled Substances Application: Synthcon LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Synthcon LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTAL INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2022. Such persons may also file a written request for a hearing on the application on or before April 26, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on December 2, 2021,

Synthcon LLC, 770 Wooten Road, Suite 101, Colorado Springs, Colorado 80915–3538, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
3-FMC	1233	I
Cathinone	1235	I
Methcathinone	1237	I
4-FMC	1238	I
Pentedrone	1246	I
Mephedrone(4-Methyl-N-methylcathinone)	1248	I
4-MEC	1249	I
Naphyrone	1258	I
N-Ethylamphetamine	1475	I
N,N-Dimethylamphetamine	1480	I
Aminorex	1585	I
Cis-4-Methylaminorex	1590	I
GHB	2010	I
Methaqualone	2565	I
Mecloqualone	2572	I
JWH-250	6250	I
ADB-PINACA	7035	I
JWH-018	7118	I
JWH-073	7173	I
JWH-200	7200	I
JWH-203	7203	I
4-Methyl-alpha-ethylaminopentiophenone	7245	I
N-Ethyhexedrone	7246	I
AET	7249	I
Ibogaine	7260	I
CP-47,497	7297	I
CP-47,497 C8 HOMOLOG	7298	I
LSD	7315	I
2C-T-7	7348	I
Tetrahydrocannabinols	7370	I
Mescaline	7381	I
2C-T-2	7385	I
3,4,5-TMA	7390	I
DOB	7391	I
2CB	7392	I
DOM	7395	I
2,5-DMA	7396	I
JWH-398	7398	I
DOE	7399	I
MDA	7400	I
5-METHOXY-MDA	7401	I
N-HYDROXY-MDA	7402	I
MDEA	7404	I
MDMA	7405	I
PMA	7411	I
5-MeO-DMT	7431	I
AMT	7432	I
Bufotenine	7433	I
DET	7434	I
DMT	7435	I
Psilocybin	7437	I
Psilocin	7438	I
5-Methoxy-N,N-diisopropyltryptamine	7439	I
4-Methyl-alpha-pyrrolidinohexiophenone	7446	I
PCE	7455	I
PCPy	7458	I
TCP	7470	I
TCPy	7473	I
JB323	7482	I
JB336	7484	I
BZP	7493	I
4-MePPP	7498	I
2C-D	7508	I
2C-E	7509	I
2C-H	7517	I
2C-I	7518	I
2C-C	7519	I
2C-N	7521	I
2C-P	7524	I
2C-T-4	7532	I

Controlled substance	Drug code	Schedule
MDPV	7535	I
25B-NBOME	7536	I
25C-NBOME	7537	I
25I-NBOME	7538	I
Methylone	7540	I
Butylone	7541	I
Pentylone	7542	I
N-Ethylpentyloe	7543	I
Alpha-Pyrrolidinohexanophenone	7544	I
Alpha-PVP	7545	I
Alpha-PBP	7546	I
Ethylone	7547	I
AM-694	7694	I
Etorphine	9056	I
Heroin	9200	I
Normorphine	9313	I
Acetorphine	9319	I
U-47700	9547	I
AH-7921	9551	I
MT-45	9560	I
Acetylmethadol	9601	I
Allylprodine	9602	I
Alphacetylmethadol	9603	I
Alphameprodine	9604	I
Alphamethadol	9605	I
Benzethidine	9606	I
Betacetylmethadol	9607	I
Clonitazine	9612	I
Isontonitazene	9614	I
Diampromide	9615	I
Diethylthiambutene	9616	I
Dimethylthiambutene	9619	I
Etonitazene	9624	I
Ketobemidone	9628	I
MPPP	9661	I
PEPAP	9663	I
Tilidine	9750	I
Acryl Fentanyl	9811	I
Para-fluorofentanyl	9812	I
3-Methylfentanyl	9813	I
Alpha-methylfentanyl	9814	I
Acetyl-alpha-methylfentanyl	9815	I
Ortho-fluorofentanyl	9816	I
Acetylfentanyl	9821	I
Butyrylfentanyl	9822	I
Para-fluorofentanyl	9823	I
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)	9824	I
Methoxyacetyl fentanyl	9825	I
Para-chloroisobutyryl fentanyl	9826	I
Isobutyrylfentanyl	9827	I
Beta-Hydroxyfentanyl	9830	I
Beta-Hydroxy-3-methylfentanyl	9831	I
Alpha-Methylthiofentanyl	9832	I
3-Methylthiofentanyl	9833	I
Furanylfentanyl	9834	I
Thiofentanyl	9835	I
Beta-Hydroxythiofentanyl	9836	I
Para-Methoxybutyryl Fetnanyl	9837	I
Ocfentanil	9838	I
Valeryl Fentanyl	9840	I
Tetrahydrofuranyl Fentanyl	9843	I
Crotonyl Fentanyl	9844	I
Cyclopropyl Fentanyl	9845	I
Cyclopentyl Fentanyl	9847	I
Fentanyl Related Compounds	9850	I
Amphetamine	1100	II
Methamphetamine	1105	II
1-Phenylcyclohexylamine	7460	II
PCP	7471	II
ANPP	8333	II
Norfentanyl	8366	II
P2P	8501	II
PCC	8603	II
Alphaprodine	9010	II

Controlled substance	Drug code	Schedule
Anileridine	9020	II
Cocaine	9041	II
Diphenoxylate	9170	II
Ecgonine	9180	II
Levorphanol	9220	II
Meperidine	9230	II
Meperidine Intermediate-A	9232	II
Meperidine Intermediate-B	9233	II
Meperidine Intermediate-C	9234	II
Dextropropoxyphene	9273	II
Morphine	9300	II
Levo-alphacetylmethadol	9648	II
Alfentanil	9737	II
Remifentanil	9739	II
Sufentanil	9740	II
Carfentanil	9743	II
Tapentadol	9780	II
Fentanyl	9801	II

The company plans to bulk manufacture the listed controlled substances as analytical materials, proficiency test materials, and academic research materials for distribution to its customers. No other activities for these drug codes are authorized for this registration.

Matthew J. Strait,

Deputy Assistant Administrator.

[FR Doc. 2022–04057 Filed 2–24–22; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–965]

Importer of Controlled Substances Application: Lyndra Therapeutics

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Lyndra Therapeutics has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTAL INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 28, 2022. Such persons may also file a written request for a hearing on the application on or before March 28, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on January 13, 2022, Lyndra Therapeutics, 65 Grove Street, Suite 301, Watertown, Massachusetts 02472, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Methadone	9250	II

The company plans to develop the formulation and process, and then manufacture the finished oral dosage form for use in preclinical and human clinical trials and analysis. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Matthew J. Strait,

Deputy Assistant Administrator.

[FR Doc. 2022–04061 Filed 2–24–22; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF LABOR

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Miner's Claim for Benefits and Employment History

ACTION: Notice of availability; request for comments.

SUMMARY: The Department of Labor (DOL) is submitting this Office of Workers' Compensation Programs (OWCP)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited.

DATES: The OMB will consider all written comments that the agency receives on or before March 28, 2022.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function.

Comments are invited on: (1) Whether the collection of information is necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; (2) if the information will be processed and used in a timely manner; (3) the accuracy of the agency's estimates of the burden and cost of the collection of information, including the validity of the methodology and assumptions used; (4) ways to enhance the quality, utility and clarity of the information collection; and